Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

11.03
-0.0900-0.81%
Volume:10.42K
Turnover:115.32K
Market Cap:3.74B
PE:115.64
High:11.10
Open:11.08
Low:11.03
Close:11.12
52wk High:13.11
52wk Low:6.28
Shares:339.00M
Float Shares:272.00M
Volume Ratio:0.71
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0954
EPS(LYR):-0.0211
ROE:7.36%
ROA:2.71%
PB:7.67
PE(LYR):-522.75

Loading ...

Telix H1 2026 Results: Investor Webcast Notification

GlobeNewswire
·
Jul 31

Telix Pharmaceuticals Stock And 2 Fast Growing Insider Owned ASX Shares

Simply Wall St.
·
Jul 31

Telix Stock And 2 Australian Growth Shares With High Insider Ownership

Simply Wall St.
·
Jul 28

3 Australian Growth Stocks Where Insider Ownership Could Matter Most

Simply Wall St.
·
Jul 26

Telix Stock And Other Fast Growing Insider Owned Shares Worth A Closer Look

Simply Wall St.
·
Jul 24

What Telix Pharmaceuticals (ASX:TLX)'s Upgraded US$1 Billion FY26 Outlook Means For Shareholders

Simply Wall St.
·
Jul 24

Jarden Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

TIPRANKS
·
Jul 24

3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look

Simply Wall St.
·
Jul 23

Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and CSL (OtherCMXHF)

TIPRANKS
·
Jul 23

3 Australian Growth Stocks Where Insider Ownership Signals Stronger Conviction

Simply Wall St.
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Telix Pharmaceuticals (OtherTLPPF) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Jul 22

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

GlobeNewswire
·
Jul 22

Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoY

Benzinga Earnings
·
Jul 21

Telix Pharmaceuticals Carries Meaningful Upside on Potential Product Approvals, Jefferies Says

MT Newswires Live
·
Jul 21

3 Australian Growth Stocks Trading Below Fair Value With Strong Insider Backing

Simply Wall St.
·
Jul 21

Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

TIPRANKS
·
Jul 21

Telix Pharmaceuticals Posts Higher Q2 Revenue

MT Newswires Live
·
Jul 21

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

GlobeNewswire
·
Jul 21

3 Australian Growth Stocks With High Insider Ownership Worth A Closer Look

Simply Wall St.
·
Jul 20

RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target

MT Newswires Live
·
Jul 17